ArticleJournal of pharmacokinetics and pharmacodynamics2026
Uncertainty undermines the validity of antimicrobial pharmacodynamics.
Article in Journal of pharmacokinetics and pharmacodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial therapy is informed by quantitative models of drug disposition and action. These models utilize experimental and observational evidence, subject to uncertainties, to support drug selection and dosage regimen optimization, and interpret antimicrobial resistance data. The framework includes multiple components, which characterize mechanisms contributing to therapeutic outcome. The components must be combined in a logical sequence to generate predictions, so propagation of uncertainty is a critical consideration. Quantitative evaluation of this uncertainty has received apparently little attention. This essay argues for the importance of uncertainty quantification in antimicrobial pharmacology. The impact of parameter uncertainties and measurement errors on the validity of pharmacokinetic-pharmacodynamic modelling of antimicrobials is described. Major components of the modelling workflow are assessed, and uncertainties characterized. The influence of major design and statistical analysis decisions at each step is emphasized. Finally, using detailed simulations, the impact of these sources of uncertainty on outcomes including clinical breakpoints and dose individualization is illustrated. Measurement of antimicrobial potency as the minimum inhibitory concentration contributes approximately twofold error, which is important for individual dose determination. Interpretation of PK/PD parameters is generally conducted dichotomously as thresholds, which are empirically determined, and subject to error. Parameter uncertainties in the exposure-response relationship are potentially substantial, and contribute apparently major uncertainty to predictions at both population and individual levels. The importance of uncertainty in pharmacokinetics appears context-sensitive. Applications including dose optimization or susceptibility breakpoints appear overly confident, and point estimation from these models may be an unreliable basis for decision making. These observations highlight the importance of uncertainty quantification for rigorous antimicrobial pharmacology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.